Apart from CD73 inhibition, A2AR antagonists have also been extensively studied as another clinically feasible treatment option to counteract ADO‐mediated immunosuppression, which had been proven to promote immune cell infiltration, particularly CD8+ T cells and NK cells, thereby inhibiting tumor growth and metastasis [230, 231, 232]. The gene discussed is CD8A; the disease is neoplasm.